UroGen Pharma (URGN) Competitors $11.30 -0.10 (-0.88%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. NRIX, ELVN, NTLA, BGM, RCUS, VIR, RCKT, COLL, XNCR, and REPLShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT), Collegium Pharmaceutical (COLL), Xencor (XNCR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Qilian International Holding Group Arcus Biosciences Vir Biotechnology Rocket Pharmaceuticals Collegium Pharmaceutical Xencor Replimune Group UroGen Pharma (NASDAQ:URGN) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation. Does the media refer more to URGN or NRIX? In the previous week, Nurix Therapeutics had 14 more articles in the media than UroGen Pharma. MarketBeat recorded 18 mentions for Nurix Therapeutics and 4 mentions for UroGen Pharma. Nurix Therapeutics' average media sentiment score of 0.99 beat UroGen Pharma's score of 0.88 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UroGen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in URGN or NRIX? UroGen Pharma received 292 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 77.88% of users gave Nurix Therapeutics an outperform vote while only 74.30% of users gave UroGen Pharma an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes37374.30% Underperform Votes12925.70% Nurix TherapeuticsOutperform Votes8177.88% Underperform Votes2322.12% Which has more volatility & risk, URGN or NRIX? UroGen Pharma has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Which has stronger earnings & valuation, URGN or NRIX? UroGen Pharma has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$90.40M5.76-$102.24M-$3.23-3.50Nurix Therapeutics$54.55M17.23-$193.57M-$2.89-4.29 Do insiders & institutionals have more ownership in URGN or NRIX? 91.3% of UroGen Pharma shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is URGN or NRIX more profitable? UroGen Pharma has a net margin of -129.11% compared to Nurix Therapeutics' net margin of -354.85%. UroGen Pharma's return on equity of 0.00% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Nurix Therapeutics -354.85%-53.65%-38.59% Do analysts rate URGN or NRIX? UroGen Pharma presently has a consensus price target of $38.20, suggesting a potential upside of 238.05%. Nurix Therapeutics has a consensus price target of $30.88, suggesting a potential upside of 149.29%. Given UroGen Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe UroGen Pharma is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryUroGen Pharma beats Nurix Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$520.86M$6.99B$5.68B$8.30BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-3.597.2624.6019.25Price / Sales5.76232.30388.5994.32Price / CashN/A65.6738.1634.64Price / Book-4.066.617.084.46Net Income-$102.24M$142.13M$3.19B$247.07M7 Day Performance-3.09%-1.52%-0.93%0.14%1 Month Performance20.73%-3.46%3.56%-4.39%1 Year Performance-25.51%-5.32%14.29%4.85% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma3.9015 of 5 stars$11.30-0.9%$38.20+238.1%-31.6%$520.86M$90.40M-3.59200NRIXNurix Therapeutics2.0249 of 5 stars$13.93+2.5%$30.88+121.7%-7.0%$1.06B$54.55M-4.82300ELVNEnliven Therapeutics2.8775 of 5 stars$21.04+1.4%$38.25+81.8%+19.9%$1.03BN/A-11.0750NTLAIntellia Therapeutics4.4674 of 5 stars$9.58+4.8%$37.56+292.0%-67.5%$991.69M$57.88M-1.76600Analyst RevisionBGMQilian International Holding GroupN/A$10.03+4.5%N/AN/A$975.14M$25.10M0.00298RCUSArcus Biosciences2.3158 of 5 stars$9.15-2.0%$30.25+230.5%-49.1%$962.43M$258M-2.91500VIRVir Biotechnology3.7697 of 5 stars$7.01-2.0%$35.67+408.8%-30.5%$961.37M$63.71M-1.79580Positive NewsRCKTRocket Pharmaceuticals4.7764 of 5 stars$8.83+0.8%$43.00+387.0%-69.6%$941.54MN/A-3.21240Positive NewsCOLLCollegium Pharmaceutical4.0272 of 5 stars$29.67+0.7%$43.60+46.9%-24.9%$934.19M$631.45M12.79210Analyst ForecastAnalyst RevisionXNCRXencor3.3791 of 5 stars$12.98+1.7%$34.38+164.8%-46.0%$914.60M$110.49M-4.06280REPLReplimune Group3.8306 of 5 stars$11.78+1.1%$19.43+64.9%+32.8%$907.24MN/A-3.84210Positive News Remove Ads Related Companies and Tools Related Companies Nurix Therapeutics Competitors Enliven Therapeutics Competitors Intellia Therapeutics Competitors Qilian International Holding Group Competitors Arcus Biosciences Competitors Vir Biotechnology Competitors Rocket Pharmaceuticals Competitors Collegium Pharmaceutical Competitors Xencor Competitors Replimune Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts